The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab.
Edoardo LenciLuca CantiniFederica PecciValeria CognigniVeronica AgostinelliGiulia MentrastiAlessio LupiNicoletta RanalloFrancesco PaoloniSilvia RinaldiLinda NicolardiAndrea CaglioSophie AertsAlessio CortelliniCorrado FicorellaRita ChiariMassimo Di MaioAnne-Marie C DingemansJoachim G J V AertsRossana BerardiPublished in: Journal of clinical medicine (2021)
Our data shown that GRImT1 and GRImΔ are more reliable peripheral blood biomarkers of outcome compared to GRImT0 in aNSCLC patients treated with pembrolizumab and might represent useful biomarkers to drive clinical decisions in this setting.